Patient-centric decision-making in supplements intake and disclosure in clinical practice: a novel SIDP-12 tool to prevent drug-supplement interaction [0.03%]
以患者为中心的补充剂摄取和披露临床决策：一种新型SIDP-12工具可预防药物与膳食补充剂相互作用
Sabrina Ait Gacem,Hasniza Zaman Huri,Izyan A Wahab et al.
Sabrina Ait Gacem et al.
Background: Self-treatment of dietary supplements may contribute to interactions and severe side effects. Limited studies have constructed a scale that can measure the disclosure practice of supplements to healthcare prov...
Adverse events of topical ocular prostaglandin medications for glaucoma treatment: a pharmacovigilance study based on the FAERS database [0.03%]
基于FAERS数据库青光眼治疗用前列腺素类滴眼液的不良事件药物流行病学研究
Shi-Nan Wu,Caihong Huang,Yu-Qian Wang et al.
Shi-Nan Wu et al.
Background: As prostaglandin medications, crucial in glaucoma treatment, become more widely used, their local adverse events are increasingly observed. Ob...
An integrative systematic review of nurses' involvement in medication deprescription in long-term healthcare settings for older people [0.03%]
护理人员参与老年人长期护理机构减药工作的综合系统回顾
Mojtaba Vaismoradi,Abbas Mardani,Manuel Lillo Crespo et al.
Mojtaba Vaismoradi et al.
Background: Deprescription of medications for older people in long-term care settings is crucial to enhance medication safety by reducing polypharmacy and minimizing related adverse events. Nurses as the member of the mul...
Enhancing medication management of older adults in Qatar: healthcare professionals' perspectives on challenges, barriers and enabling solutions [0.03%]
卡塔尔老年人用药管理的改善：医疗专业人员视角下的挑战、障碍及解决方案
Ameena Alyazeedi,Carrie Stewart,Roy L Soiza et al.
Ameena Alyazeedi et al.
Background: Polypharmacy and potentially inappropriate medications are significant challenges in older adults' medication management. The Consolidated Framework for Implementation Research (CFIR) is a comprehensive approa...
Effect of a closed-loop medication order executive system on safe medication administration at a tertiary hospital: a quasi-experimental study [0.03%]
闭环医嘱执行系统对三甲医院用药安全影响的准实验研究
Xuwen Yin,Haiyan Song,Jieyu Lu et al.
Xuwen Yin et al.
Background: Closed-loop electronic medication management systems are effective measures for preventing medication errors (MEs). However, there is limited evidence supporting this, and few studies have evaluated the long-t...
Disproportionality analysis of reslizumab based on the FDA Adverse Event Reporting System [0.03%]
基于FDA不良事件报告系统分析瑞利珠单抗的信号比例度研究
Huqun Li,Cuilian Guo,Chongshu Wang
Huqun Li
Background: With the increasing prescription of reslizumab for severe asthma with an eosinophilic phenotype, a real-world pharmacovigilance analysis of reslizumab is urgently required to detect potential unreported advers...
Exploring the community pharmacist's knowledge, attitude, and practices regarding adverse drug reactions and its reporting in the United Arab Emirates: a survey-based cross-sectional study [0.03%]
基于横断面调查的关于阿拉伯联合酋长国社区药剂师的药品不良反应知识、态度和行为及其上报情况的研究
Javedh Shareef,Sathvik Belagodu Sridhar,Mullaicharam Bhupathyraaj et al.
Javedh Shareef et al.
Background: Adverse drug reactions (ADRs) contribute significant clinical and economic burden to the country's healthcare system globally. Prompt reporting of ADRs by the community pharmacist is essential to the active ph...
A disproportionality analysis for assessing the safety of FLT3 inhibitors using the FDA Adverse Event Reporting System (FAERS) [0.03%]
基于FDA不良事件报告系统评估FLT3抑制剂安全性的不平衡分析
Jie Zhou,Jinping Zhang,Qiaoyun Wang et al.
Jie Zhou et al.
Objectives: This pharmacovigilance analysis was conducted to assess the safety signals of FMS-related tyrosine kinase 3 (FLT3) inhibitors in a real-world setting using the United States Food and Drug Administration Advers...
Adverse event profiles of CDK4/6 inhibitors: data mining and disproportionality analysis of the FDA adverse event reporting system [0.03%]
基于FDA不良事件报告系统的CDK4/6抑制剂类药物的不良事件特征及 disproportionality分析
Jun Shen,Pingli Luo,Jianmei Xu
Jun Shen
Background: Cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors are targeted therapies designed to selectively block CDK4/6, crucial regulators of the cell cycle. These inhibitors play a pivotal role in restoring cell cy...
Safety profile of drugs used in non-cystic fibrosis bronchiectasis: a narrative review [0.03%]
非囊性纤维化支气管扩张症用药的安全性：综述型研究
Henil Upadhyay,Stefano Aliberti,Andrew Husband et al.
Henil Upadhyay et al.
Non-cystic fibrosis bronchiectasis is a long-term lung disease characterised by abnormal dilatation of the bronchi, with patients experiencing chronic productive cough and recurrent exacerbations. Currently, there are no licensed drugs for ...